TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $125M
Founded date: 2015
Investors 6
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | Syno Capit... | synocapita... |
| - | 6 Dimensio... | 6dimension... |
| - | Curative V... | curativeve... |
| - | BioImpact ... | bioimpactc... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.03.2018 | Series B | $125M | - |
Mentions in press and media 7
| Date | Title | Description |
| 20.01.2021 | TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock | - |
| 31.12.2018 | Next-gen T cell player TCR2 Therapeutics sets stage for $100M-plus IPO as MPM's Baeuerle caps prolific year | Patrick Baeuerle Patrick Baeuerle has been busy. Right after steering next-gen BiTE company Harpoon Therapeutics toward an IPO, the MPM partner and immunologist is shepherding another oncology company with preclin... |
| 22.03.2018 | Term Sheet — Thursday, March 22 | THE VC WAR CHEST Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop Sequoia Capital is raising as much as $12 billion between its global growth fund and other venture capital and gr... |
| 21.03.2018 | MPM Portfolio Company TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing | - |
| 21.03.2018 | TCR2 Therapeutics Raises $125M in Series B Financing | TCR2 Therapeutics Inc., a Cambridge, MA-based immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, completed a $125m Series B financing. The round was co-led ... |
| 21.03.2018 | TCR2 Therapeutics Rakes in $125M in Series B | CAMBRIDGE, MA, Immuno-oncology company announced today the completion of an oversubscribed Series B financing of $125 million. >> Click here for more funding data on TCR2 Therapeutics >> To export TCR2 Therapeutics funding d... |
| 21.03.2018 | TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing | TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today the completion of an oversubscribed Series B financing of $125... |